Clinical value of cell-based assays in the characterization of seronegative myasthenia gravis
This study investigated the use of live cell-based assays (l-CBAs) in patients with seronegative MG (SNMG) who are negative for AChR and MUSK antibodies. The results showed that one-third of SNMG patients had AChR or MuSK antibodies detectable by l-CBAs, and a combined AChR-MuSK l-CBA efficiently detected these antibodies. Patients with antibody positivity or triple seronegative status had a milder disease course and better clinical outcomes when immunotherapy was initiated early. The study suggests that performing CBAs can be a valuable diagnostic tool for SNMG and may improve treatment decisions.